These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16491106)

  • 1. Bruising associated with sibutramine: results from postmarketing surveillance in New Zealand.
    Harrison-Woolrych M; Hill GR; Clark DW
    Int J Obes (Lond); 2006 Aug; 30(8):1315-7. PubMed ID: 16491106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sibutramine usage in New Zealand: an analysis of prescription data by the Intensive Medicines Monitoring Programme.
    Hill GR; Ashton J; Harrison-Woolrych M
    Pharmacoepidemiol Drug Saf; 2007 Nov; 16(11):1217-26. PubMed ID: 17661435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ; Wilton LV; Shakir SA
    Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. QT interval prolongation associated with sibutramine treatment.
    Harrison-Woolrych M; Clark DW; Hill GR; Rees MI; Skinner JR
    Br J Clin Pharmacol; 2006 Apr; 61(4):464-9. PubMed ID: 16542208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study.
    Harrison-Woolrych M; Ashton J; Herbison P
    Drug Saf; 2010 Jul; 33(7):605-13. PubMed ID: 20553061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial.
    Maggioni AP; Caterson I; Coutinho W; Finer N; Gaal LV; Sharma AM; Torp-Pedersen C; Bacher P; Shepherd G; Sun R; James P;
    J Cardiovasc Pharmacol; 2008 Nov; 52(5):393-402. PubMed ID: 19033818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sibutramine: EMEA under industry's thumb.
    Prescrire Int; 2003 Jun; 12(65):102. PubMed ID: 12825579
    [No Abstract]   [Full Text] [Related]  

  • 8. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL; Apovian CM; Aronne LJ; Fernstrom MH; Frank A; Greenway FL; Heber D; Kushner RF; Cwik KM; Walch JK; Hewkin AC; Blakesley V
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sibutramine-associated adverse effects: a practical guide for its safe use.
    Florentin M; Liberopoulos EN; Elisaf MS
    Obes Rev; 2008 Jul; 9(4):378-87. PubMed ID: 18034790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European Medicines Agency withdrawal for sibutramine.
    Galhardo J; Davis N; Matthai S; Shield JP
    Arch Dis Child; 2010 Oct; 95(10):856. PubMed ID: 20573736
    [No Abstract]   [Full Text] [Related]  

  • 11. Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme.
    Hill GR; Harrison-Woolrych M
    N Z Med J; 2008 Oct; 121(1283):68-75. PubMed ID: 18841187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany.
    Brennan A; Ara R; Sterz R; Matiba B; Bergemann R
    Eur J Health Econ; 2006 Dec; 7(4):276-84. PubMed ID: 17063345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Adverse drug reactions of a slimming product contaminated with sibutramine].
    van Hunsel F; van Grootheest K
    Ned Tijdschr Geneeskd; 2011; 155(42):A3695. PubMed ID: 22027464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hair loss with use of the levonorgestrel intrauterine device.
    Paterson H; Clifton J; Miller D; Ashton J; Harrison-Woolrych M
    Contraception; 2007 Oct; 76(4):306-9. PubMed ID: 17900442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sibutramine: an Australian analysis of reported adverse effects.
    Prescrire Int; 2007 Jun; 16(89):114. PubMed ID: 17590911
    [No Abstract]   [Full Text] [Related]  

  • 16. Privacy issues and the monitoring of sumatriptan in the New Zealand Intensive Medicines Monitoring Programme.
    Coulter DM
    Pharmacoepidemiol Drug Saf; 2001 Dec; 10(7):663-7. PubMed ID: 11980258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sibutramine-associated QT interval prolongation and cardiac arrest.
    Ernest D; Gershenzon A; Corallo CE; Nagappan R
    Ann Pharmacother; 2008 Oct; 42(10):1514-7. PubMed ID: 18728104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sibutramine-induced acute myocardial infarction in a young lady.
    Yim KM; Ng HW; Chan CK; Yip G; Lau FL
    Clin Toxicol (Phila); 2008 Nov; 46(9):877-9. PubMed ID: 18788006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sibutramine and psychosis.
    Litvan L; Alcoverro-Fortuny O
    J Clin Psychopharmacol; 2007 Dec; 27(6):726-7. PubMed ID: 18004153
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular effects of sibutramine in the treatment of obese adolescents: results of a randomized, double-blind, placebo-controlled study.
    Daniels SR; Long B; Crow S; Styne D; Sothern M; Vargas-Rodriguez I; Harris L; Walch J; Jasinsky O; Cwik K; Hewkin A; Blakesley V;
    Pediatrics; 2007 Jul; 120(1):e147-57. PubMed ID: 17576783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.